Subscribe to RSS
DOI: 10.1055/s-2005-858579
© Georg Thieme Verlag KG Stuttgart · New York
Lebensqualität bei chronisch entzündlichen Darmerkrankungen (CED): die deutsche Version des Inflammatory Bowel Disease Questionnaire (IBDQ-D) zur krankheitsspezifischen Lebensqualitätsmessung – erste Anwendung und Vergleich mit anderen internationalen Fassungen
Quality of Life Assessment in Inflammatory Bowel Disease (IBD): German Version of the Inflammatory Bowel Disease Questionnaire (IBDQ-D; Disease-Specific Instrument for Quality of Life Assessment) – First Application and Comparison with International InvestigationsPublication History
Publication Date:
11 October 2005 (online)
Zusammenfassung
Einleitung: Die gesundheitsbezogene Lebensqualität (health-related quality of life, HRQOL) spielt im Gesundheitswesen eine zunehmende Rolle. Die Arbeitsgruppe Lebensqualität im Kompetenznetz chronisch entzündliche Darmerkrankungen hat zum Ziel, Instrumente der HRQOL-Messung zu erarbeiten und als Standards in die klinische Versorgung und Forschung zu integrieren. Methodik: Der „Inflammatory Bowel Disease Questionnaire” (IBDQ) hat sich international als valides krankheitsspezifisches HRQOL-Messinstrument erwiesen. Eine deutsche Version (IBDQ-D) wurde jetzt von uns entwickelt und bei 415 ambulant betreuten Patienten mit Morbus Crohn (MC; n = 306) oder Colitis ulcerosa (CU; n = 109) erstmals geprüft. Ziel war, durch die Testung psychometrischer Eigenschaften, durch Vergleich der erhaltenen IBDQ-D-Werte mit den Ergebnissen internationaler Varianten sowie durch die Korrelation der IBDQ-Werte mit der Krankheitsaktivität, die Qualität der generierten deutschen Version zu prüfen. Ergebnisse: Die getesteten psychometrischen Eigenschaften ergaben keine Hinweise auf die Notwendigkeit einer wesentlichen Überarbeitung des IBDQ-D. Der Vergleich zu internationalen Daten deutet darauf hin, dass der IBDQ-D ein robustes Messinstrument der HRQOL von deutschsprachigen MC- und CU-Patienten darstellt. Für beide Erkrankungen findet sich zwischen der Krankheitsaktivität und dem IBDQ-D-Gesamtscore eine statistisch signifikante negative Korrelation. Mit Hilfe des IBDQ-D ist es möglich, die Messung der HRQOL als Endpunkt für klinische Studien im Bereich CED in Deutschland zu etablieren.
Abstract
Background: Health-related quality of life (HRQOL) is an important outcome-parameter in health research and care. The aim of the working group Quality of Life in the Competence Network Inflammatory Bowel Disease (IBD; in the original German: “Kompetenznetz chronisch entzündliche Darmerkrankungen”) is to generate instruments for assessment of HRQOL and its implementation as standards in clinical trials, health care and research in IBD. Methods: The Inflammatory Bowel Disease Questionnaire (IBDQ) is an international validated disease specific instrument for HRQOL-assessment. A German version of the IBDQ was elaborated and tested in 415 outpatients with Crohn’s disease (CD, n = 306) and ulcerative colitis (UC, n = 109). The aim of the study was to compare the results of HRQOL-assessment (IBDQ-D) with international investigations, to correlate HRQOL results with disease activity and to preform a pretest of psychometric properties. Results: International data suggest that the IBDQ-D is a suitable instrument for HRQOL-assessment in CD and UC. For both disease a statistically significant negative correlation with disease activity was found. Tested psychometric properties do not suggest that a revision of the IBDQ-D is required. The IBDQ-D offers the HRQOL-assessment as an primary or secondary outcome in clinical trials in IBD in Germany.
Schlüsselwörter
Gesundheitsbezogene Lebensqualität - chronisch entzündliche Darmerkrankung - Morbus Crohn - Colitis ulcerosa - IBDQ-D
Key words
Health-related quality of life - inflammatory bowel disease - Crohn’s disease - ulcerative colitis - IBDQ-D
Literatur
- 1 Häuser W, Grandt D. Lebensqualitätsmessung in der Gastroenterologie – Konzepte, Instrumente und Probleme. Z Gastroenterol. 2001; 39 475-481
- 2 Lopez-Vivancos J, Casellas F, Badia X. et al . Validation of the Spanish Version of the Inflammatory Bowel Disease Questionnaire on Ulcerative Colitis and Crohn’s Disease. Digestion. 1999; 60 274-280
- 3 Guyatt G, Mitchell A, Irvine E J. et al . A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989; 96 (3) 804-810
- 4 Irvine E J. Quality of Life – Rationale and Methods for Developing a Disease-specific Instrument for Inflammatory Bowel Disease. Scand J Gastroenterol. 1993; 28 Suppl 199 22-27
- 5 Love J R, Irvine E J, Fedorak N. Quality of Life in Inflammatory Bowel Disease. J Clin Gastroenterol. 1992; 14 (1) 15-19
- 6 Drossmann D A. Inflammatory Bowel Disease. Spilker B. Quality of Life and Pharmacoeconomics in Clinical Trials 2nd Edition Philadelphia; Lippincott-Raven 1996: 925-935
- 7 Drossmann D A, Patrick D L, Mitchel C M. et al . Health-related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns. Dig Dis Sci. 1989; 34 1379-1386
- 8 Testa M A, Simson D C. Assessment of Quality of life outcomes. New England Journal of Medicine. 1996; 334 (13) 835-840
-
9
www.who.int/about/definition/en.
- 10 Ellert U, Knopf H. Satisfaction with living conditions and health. Gesundheitswesen. 1999; 61 145-150
- 11 Priebe S, Kaiser W, Huxley P. Quality of life as a planning and evaluation criterion in psychiatric management. Gesundheitswesen. 1996; 58 (Suppl 1) 86-90
- 12 Ravens-Sieberer U, Holling H, Bettge S. et al . Assessment of psychological health and quality of life with The Child and Adolescent Health Survey. Gesundheitswesen. 2002; 64 (Suppl 1) 30-35
- 13 Mitchell A, Guyatt G, Singer J. et al . Quality of life in patients with inflammatory bowel disease. J Clin Gastroenterol. 1988; 10 306-310
- 14 Pukrop R, Möller H J, Saß H. et al . Quality of Life. A contribution to construct validation and the development of a modular system. Nervenarzt. 1999; 70 41-53
- 15 Han S W, McColl E, Steen N. et al . The Inflammatory Bowel Disease Questionnaire: A Valid and Reliable Measure in Ulcerative Colitis Patients in the North East of England. Scand J Gastroenterol. 1998; 33 961-966
- 16 de Boer AGEM. et al . Inflammatory Bowel Disease Questionnaire: cross-cultural adaption and further validation. European Journal of Gastroenterology &. Hepatology. 1995; 7 1043-1050
- 17 Russel M GVM. et al . Validation of the Dutch Translation of the Inflammatory Bowel Disease Questionnaire (IBDQ): A Health-Related Quality of Life Questionnaire in Inflammatory Bowel Disease. Digestion. 1997; 58 (3) 282-288
- 18 Kim W H. et al . Quality of life in Koreans patients with inflammatory bowel diseases: ulcerative colitis, Crohn’s disease and intestinal Behcet’s disease. Int J Colorect Dis. 1999; 14 52-57
- 19 Pallis A G, Vlachonikolis I G, Mouzas I G. Quality of life of Greek patients with inflammatory bowel disease. Validation of the Greek translation of the inflammatory bowel disease questionnaire. Digestion. 2001; 63 240-246
- 20 Bernklev T, Moum B, Moum T (IBSEN). Quality of life in patients with inflammatory bowel disease: translation, data quality, scaling assumptions, validity, reliability and sensitivity to change of the norwegian version of IBDQ. Scand J Gastroenterol. 2002; 37 1164-1174
- 21 Hjortswang H. et al . Validation of the inflammatory bowel disease questionnaire in Swedish patients with ulcerative colitis. Scand J Gastroenterol. 2001; 36 77-85
- 22 Leong R WL. et al . Quality of life in Chinese patients with inflammatory bowel disease: validation of the Chinese translation of the inflammatory bowel disease questionnaire. Aliment Pharmacol Ther. 2003; 17 711-718
- 23 Cheung W Y. et al . The UK IBDQ – a British version of the inflammatory bowel disease questionnaire: development and validation. J Clin Epidemiol. 2000; 53 297-306
- 24 Irvine E J, Feagan B G, Wong C J. Does self-administration of a quality of life index for inflammatory bowel disease change the results?. J Clin Epidemiol. 1996; 49 1177-1185
- 25 Irvine E J, Feagan B, Rochon J. et al . (CCRPT). Quality of Life: A Valid and Reliable Measure of Therapeutic Efficacy in the Treatment of Inflammatory Bowel Disease. Gastroenterology. 1994; 106 287-296
- 26 Sutherland M F, Beck I T, Anderson A H. et al . Oral 5ASA versus prednisone in short term treatment of Crohn’s disease: a multicentre controlled trial. Can J Gastroenterol. 1990; 4 452-457
-
27
www.kompetenznetz-ced.de/www.kompetenznetze-medizin.de.
- 28 Janke K H, Raible A, Bauer M. et al . Questions on Life Satisfaction (FLZM = Instrument zur LQ-Erfassung) in inflammatory bowel disease. Int J Colorectal Dis. 2004; 19 (4) 343-353
- 29 Snaith P, Zigmont A S. Hospital anxiety and depression scale: HADS-D. Herrmann C, Buss U. Deutsche Version; ein Fragebogen zur Erfassung von Angst und Depressivität in der somatischen Medizin; Testdokumentation und Handanweisung Bern; Huber 1995
- 30 Deutsche Arbeitsgemeinschaft Epidemiologie (DAE), Arbeitsgruppe Epidemiologische Methoden .Messung und Quantifizierung soziographischer Merkmale in epidemiologischen Studien. In: Deutsche Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie (GMDS), Deutsche Gesellschaft für Sozialmedizin und Prävention (DGSMP), Deutsche Region der Internationalen Biometrischen Gesellschaft (DR-IBS). 1999; DAE-Website: http://medweb.uni.muenster.de/institute/epi/dae/vorstand.htm#gep
- 31 Hoffmann W, Latza U, Terschuren C. Guidelines and recommendations for ensuring Good Epidemiological Practice (GEP) – revised version after evaluation. Gesundheitswesen. 2005; 67 (3) 217-225
- 32 Kohlmann T, Bullinger M, Kirchberger-Blumstein I. Die deutsche Version des Nottingham Health Profile (NHP): Übersetzungsmethodik und psychometrische Validierung. Sozial- und Präventivmedizin. 1997; 42 (3) 175-185
- 33 Mathias S D, Fifer S K, Patrick D L. Rapid translation of quality of life measures for international clinical trials: avoiding errors in the minimalist approach. Quality of Life Research. 1994; 3 403-412
- 34 Best W R, Becktel J M, Singelton J W. et al . Development of a Crohn’s disease activity index. National Cooperative Crohn’s disease study. Gastroenterology. 1976; 70 439-444
- 35 Kjeldsen J, Schafalitzky de Muckadell OB. Review – Assessment of Disease Severity and Activity in Inflammatory Bowel Disease. Scand J Gastroenterol. 1993; 28 1-9
- 36 Harvey R F, Bradshaw J M. A simple index of Crohn’s disease activity. Lancet. 1980; 1 514
- 37 Myren J, Bouchier I AD, Watkinson G. et al . The O.M.G.E. multinational inflammatory bowel disease survey 1976 – 1982. A further report on 2,657 cases. Scand J Gastroenterol. 1984; 19 (Suppl. 95) 1-27
-
38 WHO Technical Report Series No. 854. .Geneva; WHO 1995. http://chd-taskforce.de/guidelines/kap22.htm and http://www.who.int/dsa/cat98/nut8.htm#Obesity (and Poverty)
- 39 Rachmilewitz D. Coated mesalazine (5-amino-salicylic acid) versus sulpasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J. 1989; 198 82-86
- 40 Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol. 1993; 46 1417-1432
- 41 Pallis A G, Vlachonikolis I G, Mouzas I G. Assessing health-related quality of life in patients with inflammatory bowel disease, in Crete, Greece. BMC Gastroenterology. 2002; 2 1 , http://www.biomedcentral.com/1471 – 230X/2/1
- 42 Nordin K, Pahllman L, Larsson K. et al . Health related quality of life and psychological distress in a population-based sample of Swedish patients with inflammatory bowel disease. Scand J Gastroenterol. 2002; 37 450-457
- 43 Latza U, Stang A, Bergmann M. et al . The problem of response in epidemiological studies in Germany (part 1). Gesundheitswesen. 2004; 66 (5) 326-336
- 44 Hoffmann W, Terschuren C, Holle R. et al . The problem of response in epidemiological studies in Germany (part 2). Gesundheitswesen. 2004; 66 (8 – 9) 482-491
- 45 Irvine E J. Quality of Life in Inflammatory Bowel Disease: Biases and Other Factors Affecting Scores. Scand J Gastroenterol. 1995; 208 136-140
- 46 Cellier C, Sahmoud T, Froguel E. et al. and the Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives . Correlation between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn’s disease. A prospective multicenter study of 121 cases. Gut. 1994; 35 231-235
- 47 Sandborn W J, Feagan B G, Hanauer S B. et al . A Review of Activity Indices and Efficacy Endpoints for Clinical Trials of Medical Therapy in Adults With Crohn’s Disease. Gastroenterology. 2002; 122 512-530
Dr. med. W. Häuser
Klinikum Saarbrücken, Medizinische Klinik I
Winterberg 1
66119 Saarbrücken
Email: whaeuser@klinikum-saarbruecken.de